“From1 April 2015 , all registered providers must meet the new duty of candour regulation. The aim is to ensure that providers are open and transparent with people who use services. It also sets out specific requirements when things go wrong with care and treatment, including informing people about an incident, providing reasonable support, providing truthful information and an apology. ….. Bidders must provide details on how they will manage patient identifiable information in England, Scotland and Wales. This should include details on how they would secure approval requirements relating to Section 251 support under the Health and Social Care Act, ….. “ (iii) Under element 4: Service user involvement: “The perinatal mortality review tool should incorporate the parents’ perspective about the care they and their baby received during the antenatal, intrapartum and postnatal period and any concerns they raised about their care. However, the parents’ perspective will be inputted into the tool through health professionals – parents will not have direct access to the tool. Parents must be fully informed about the outcomes of the review.”
“Data confidentiality. How will good practice be followed in ensuring patient confidentiality? Will section 60/section 251 Health and Social Care Act/ NHS act approval be required from the Confidentiality Advisory Committee (CAG) or will explicit patient consent be sought? Is there a plan for acquiring approval?”
“Regulations under subsection (1) may not make provision requiring the processing of confidential patient information for any purpose if it would be reasonably practicable to achieve that purpose otherwise than pursuant to such regulations, having regard to the cost of and the technology available for achieving that purpose.” (iii) Pursuant to this power, the Secretary of State has made theHealth Service (Control of Patient Information) Regulations 2002 . (iv) Under these regulations, confidential patient information may be processed for specified types of or aspects of medical research if that processing has been approved by the Health Research Authority (“HRA”). (v) HRA has itself established a Confidentiality Advisory Group (“CAG”) to advise it on applications for approval. (vi) HRA published “Principles of Advice” which sought to clarify the position of CAG in its approach to public interest and “reasonably practicable alternative”
“The regulations cannot be used to set aside the common law duty of confidence if it would be “reasonably practicable” to achieve the purposes of the processing “otherwise than pursuant to the regulations”. …………. Typically, when considering its advice on the issue of reasonable practicability the question that CAG has to consider is: Is it reasonable to expect the applicant, in practice, to either seek consent for the proposed use of confidential patient information or to achieve their purposes using data in a de-identified form. “ (vii) PI also identifies a position paper published by the HRA which, amongst other things, states that “s.251 support to access the confidential patient information of the living, without consent, cannot usually be given if a patient has been asked to give explicit consent to that processing and has not responded to the request.”
“(a) If damages are an adequate remedy, that will normally be sufficient to defeat an application for an interim injunction, but that will not always be so …. (b) in more recent times, the simple concept of the adequacy of damages has been modified at least to an extent, so that the court must assess whether it is just, in all the circumstances, that the claimant be confined to his remedy of damages …”
“In my view, a non-profit making organisation, which has bid for a contract making no allowance for profit at all, and a minimal amount for overheads, is entitled to say that, in such circumstances, damages would not be an adequate remedy.”